Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed, on April 18, 2024, Atlantic Coastal Acquisition Corp. II (“we,” “ACAB” or the “Company”) received notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has failed to maintain a minimum market value of publicly held shares of $15,000,000 for the 30 consecutive trading day such date, as required under Nasdaq Listing Rule 5450(b)(2)(C) (the “Market Value of Publicly Held Shares Requirement”).
Additionally, on July 31, 2024, we received an notice from Nasdaq informing us that we have failed to comply with Nasdaq Listing Rule 5450(a)(2), which requires a minimum of 400 unrestricted round lot holders (with at least 50% of such holders holding unrestricted securities) of our listed securities (the “Total Holders Requirement” and, together with the Market Value of Publicly Held Shares Requirements, the “Nasdaq Deficiencies”).
As previously disclosed, the Company was granted a compliance period to cure the Nasdaq Deficiencies no later than October 15, 2024. The Company expected, and still expects, the Nasdaq Deficiencies to be cured as a result of its previously announced proposed business combination (the “Business Combination”) with Abpro Corporation (“Abpro”).
On October 16, 2024, we received a delisting determination letter (“Delisting Determination Letter”) from Nasdaq notifying us that we failed to regain compliance with the Nasdaq Deficiencies by the expiration of the October 15, 2024 compliance period referenced above. Additionally, the Delisting Determination Letter also noted that, as of September 10, 2024, we failed to meet the minimum requirement of 750,000 publicly held shares of our listed common stock under Nasdaq Listing Rule 5450(b)(1)(B). The Delisting Determination Letter states that unless we request a hearing before a Nasdaq Hearing Panel (“Panel”) by October 23, 2024, trading of our common stock and warrants would be suspended.
We intend to request a hearing before the Panel prior to October 23, 2024, and such request for a hearing will automatically stay any suspension/delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires. We expect that we will regain compliance with each of the foregoing Nasdaq listing rules upon the closing of the Business Combination.
Item 8.01 Other Events.
On October 16, 2024, the Company, by resolution of the board of directors of the Company, in accordance with the Company’s Amended and Restated Certificate of Incorporation (as amended), extended the expiration date of the amount of time that the Company has available to complete a business combination from October 19, 2024 to November 19, 2024.
On October 18, 2024, the Company’s Registration Statement on Form S-4 (the “Registration Statement”) relating to the Business Combination went effective.
Important Information and Where to Find It
In connection with the Business Combination and the transactions contemplated thereby (the “Proposed Transactions”), ACAB has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission (the “SEC”), which includes the Proxy Statement distributed to holders of ACAB’s common stock in connection with ACAB’s solicitation of proxies for the vote by ACAB’s stockholders with respect to the Proposed Transactions and other matters as described in the Registration Statement, a prospectus relating to the offer of the securities to be issued to stockholders in connection with the Proposed Transactions. ACAB has mailed a definitive proxy statement/prospectus to its stockholders. Investors and security holders and other interested parties are urged to read the proxy statement/prospectus, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about ACAB, Abpro